ReviewCurrent opinion in hematology2009
Advancements in the molecular pathogenesis of myelodysplastic syndrome.
Review in Current opinion in hematology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 41 citations in OpenAlex.
- Combining lenalidomide with IL-2 family of cytokines enhances activating receptor and perforin/granzyme expression in NK cells.PloS one · 2026Article
- Article
- Kynurenines as a Novel Target for the Treatment of Malignancies.Pharmaceuticals (Basel, Switzerland) · 2021Review
- The microenvironment in myelodysplastic syndromes: Niche-mediated disease initiation and progression.Experimental hematology · 2017Review
- A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes.Blood advances · 2017Article
- Article
- Bone Marrow Immunity and Myelodysplasia.Frontiers in oncology · 2016Review
- Biology of BM failure syndromes: role of microenvironment and niches.Hematology. American Society of Hematology. Education Program · 2014Review
- hTERT deficiency in naïve T cells affects lymphocyte homeostasis in myelodysplastic syndrome patients.Oncoimmunology · 2013Article
- Effector memory regulatory T-cell expansion marks a pivotal point of immune escape in myelodysplastic syndromes.Oncoimmunology · 2013Article
- Myelodysplastic syndromes: revisiting the role of the bone marrow microenvironment in disease pathogenesis.International journal of hematology · 2012Review
- Combination strategies in myelodysplastic syndromes.International journal of hematology · 2012Review
- Management of lower-risk myelodysplastic syndromes: the art and evidence.Current hematologic malignancy reports · 2011Review
- Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.Drugs · 2011Review
- Myelodysplastic syndromes: an update on molecular pathology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2010Review
Corrections and comments
- Commented on byMyeloid disease.2009
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewMyelodysplastic syndrome is an important hematological malignancy affecting the expanding aged population. Our understanding of the biology of this disease has been limited by the heterogeneous clinicopathological features, difficulty in creating animal models, and paucity of evidence linking molecular abnormalities to disease pathogenesis. The importance of new advances in myelodysplastic syndrome will be discussed in this review. RECENT
findingsHeightened awareness of the myelodysplastic syndrome burden has garnered rising interest in the development of new treatment strategies and investigation of the molecular basis of this complex disease. A multistep process explains the heterogeneity observed in myelodysplastic syndrome better than a single event, whereby multiple biological forces culminate in telomere erosion and genomic instability. Intrinsic genetic factors within myeloid progenitors along with extrinsic factors in the microenvironment may foster clonal selection. Specific targeted intervention at critical stages along this multistep pathway, prior to acute myeloid leukemia transformation, may produce the best clinical outcome. SUMMARY: Newly identified molecular defects, the creation of animal models, and several advancements in our understanding of the molecular pathogenesis have dramatically improved diagnostic and therapeutic potential of myelodysplastic syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.